Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Abstract Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on patients’ quality of life....
Ausführliche Beschreibung

Gespeichert in:
Autor*in:

Randhawa, Jasleen [verfasserIn]

Ostojic, Alen

Vrhovac, Radovan

Atallah, Ehab

Verstovsek, Srdan

Format:

E-Artikel

Sprache:

Englisch

Erschienen:

2012

Schlagwörter:

JAK2 inhibitor

Myeloproliferative neoplasms

Myelofibrosis

JAK2V617F mutation

Splenomegaly

Anmerkung:

© Randhawa et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (

Übergeordnetes Werk:

Enthalten in: Journal of hematology & oncology - London : Biomed Central, 2008, 5(2012), 1 vom: 01. Aug.

Übergeordnetes Werk:

volume:5 ; year:2012 ; number:1 ; day:01 ; month:08

Links:

Volltext

DOI / URN:

10.1186/1756-8722-5-43

Katalog-ID:

SPR029614643

Nicht das Richtige dabei?

Schreiben Sie uns!